Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 5/20 | 0.51 |
| ▸ | IDO1 | P14902 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.45 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30079765 | 0.89 | IDO1 (0.52) | ANO1IDO1GAANPSR1MEN1 | |
| SCHEMBL20446470 | 0.89 | IDO1 (0.52) | ANO1IDO1GAANPSR1MEN1 | |
| SCHEMBL27988801 | 0.87 | IDO1 (0.53) | ANO1IDO1GAANPSR1MEN1 | |
| SCHEMBL6921464 | 0.87 | IDO1 (0.50) | ANO1IDO1GAANPSR1MEN1 | |
| SCHEMBL248758 | 0.86 | GAA (0.48) | ANO1IDO1GAANPSR1MEN1 | |
| SCHEMBL4757294 | 0.84 | GAA (0.49) | ANO1IDO1GAANPSR1MEN1 | |
| SCHEMBL29793580 | 0.84 | GAA (0.49) | ANO1IDO1GAANPSR1MEN1 | |
| SCHEMBL6919952 | 0.84 | IDO1 (0.51) | ANO1IDO1GAANPSR1MEN1 | |
| SCHEMBL21987969 | 0.84 | IDO1 (0.48) | ANO1IDO1GAANPSR1MEN1 | |
| SCHEMBL23979460 | 0.83 | IDO1 (0.47) | ANO1IDO1GAANPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103833827-B | A kind of amides compound, its pharmaceutical composition, preparation method and application | 上海医药工业研究院 | 2016-08-03 | — | — | CN | disclosed |
| CN-103833827-A | Amide compounds, medicine compositions, preparation method and application thereof | SHANGHAI INST PHARM INDUSTRY | 2014-06-04 | — | — | CN | disclosed |
| US-7825126-B2 | Purine derivatives as A3 and A1 adenosine receptor agonists | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825126-B2 | Purine derivatives as A3 and A1 adenosine receptor agonists | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-02 | — | — | US | disclosed |
| US-20070232626-A1 | Purine Derivatives as A3 and A1 Adenosine Receptor Agonists | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND H (MD) | 2007-10-04 | — | — | US | disclosed |
| EP-1794162-A1 | PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006031505-A1 | PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-03-23 | — | — | WO | disclosed |
| WO-2003011222-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| EP-0900207-B1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-0923372-A4 | PYRIDINONE THROMBIN INHIBITORS | MERCK & CO INC (US) | 2001-09-05 | — | — | EP | disclosed |
| US-6017934-A | Thrombin inhibitors | MERCK & CO., INC. (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0971891-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| CN-1222909-A | Pyrazinone thrombin inhibitors | MERCK & CO INC (US) | 1999-07-14 | — | — | CN | disclosed |
| EP-0923372-A1 | PYRIDINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1999-06-23 | — | — | EP | disclosed |
| EP-0900207-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5866573-A | Pyrazinone thrombin inhibitors | MERCK & CO., INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5792779-A | CARDIOVASCULAR DISORDERS; ANGINA | MERCK & CO., INC. (US) | 1998-08-11 | — | — | US | disclosed |
| WO-1998031670-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1998-07-23 | — | — | WO | disclosed |
| WO-1997040024-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997030708-A1 | PYRIDINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232626-A1 | Purine Derivatives as A3 and A1 Adenosine Receptor Agonists | ADORA1, ADORA3, ADORA2A | ANO1 439/4885IDO1 3225/4885GAA 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.